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ABSTRACT
OBJECTIVE
To evaluate effects of remote monitoring of adjuvant 
chemotherapy related side effects via the Advanced 
Symptom Management System (ASyMS) on symptom 
burden, quality of life, supportive care needs, anxiety, 
self-efficacy, and work limitations.
DESIGN
Multicentre, repeated measures, parallel group, 
evaluator masked, stratified randomised controlled 
trial.
SETTING
Twelve cancer centres in Austria, Greece, Norway, 
Republic of Ireland, and UK.
PARTICIPANTS
829 patients with non-metastatic breast cancer, 
colorectal cancer, Hodgkin’s disease, or non-
Hodgkin’s lymphoma receiving first line adjuvant 
chemotherapy or chemotherapy for the first time in 
five years.
INTERVENTION
Patients were randomised to ASyMS (intervention; 
n=415) or standard care (control; n=414) over six 
cycles of chemotherapy.
MAIN OUTCOME MEASURES
The primary outcome was symptom burden (Memorial 
Symptom Assessment Scale; MSAS). Secondary 
outcomes were health related quality of life 
(Functional Assessment of Cancer Therapy—General; 
FACT-G), Supportive Care Needs Survey Short-Form 
(SCNS-SF34), State-Trait Anxiety Inventory—Revised 
(STAI-R), Communication and Attitudinal Self-Efficacy 
scale for cancer (CASE-Cancer), and work limitations 
questionnaire (WLQ).
RESULTS
For the intervention group, symptom burden remained 
at pre-chemotherapy treatment levels, whereas 
controls reported an increase from cycle 1 onwards 
(least squares absolute mean difference −0.15, 95% 
confidence interval −0.19 to −0.12; P<0.001; Cohen’s 
D effect size=0.5). Analysis of MSAS sub-domains 
indicated significant reductions in favour of ASyMS 
for global distress index (−0.21, −0.27 to −0.16; 
P<0.001), psychological symptoms (−0.16, −0.23 to 
−0.10; P<0.001), and physical symptoms (−0.21, −0.26 
to −0.17; P<0.001). FACT-G scores were higher in the 
intervention group across all cycles (mean difference 
4.06, 95% confidence interval 2.65 to 5.46; P<0.001), 
whereas mean scores for STAI-R trait (−1.15, −1.90 to 
−0.41; P=0.003) and STAI-R state anxiety (−1.13, −2.06 
to −0.20; P=0.02) were lower. CASE-Cancer scores were 
higher in the intervention group (mean difference 0.81, 
0.19 to 1.43; P=0.01), and most SCNS-SF34 domains 
were lower, including sexuality needs (−1.56, −3.11 to 
−0.01; P<0.05), patient care and support needs (−1.74, 
−3.31 to −0.16; P=0.03), and physical and daily living 
needs (−2.8, −5.0 to −0.6; P=0.01). Other SCNS-SF34 
domains and WLQ were not significantly different. 
Safety of ASyMS was satisfactory. Neutropenic events 
were higher in the intervention group.
CONCLUSIONS
Significant reduction in symptom burden supports 
the use of ASyMS for remote symptom monitoring in 
cancer care. A “medium” Cohen’s effect size of 0.5 
showed a sizable, positive clinical effect of ASyMS on 
patients’ symptom experiences. Remote monitoring 
systems will be vital for future services, particularly 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Effective symptom monitoring and management is essential during 
chemotherapy for cancer
Current approaches for reporting symptoms rely on patients’ retrospective recall 
and self-identification of severe symptoms to prompt contact with their clinicians
Digital remote monitoring interventions to support patients during chemotherapy 
are available, but very few were evaluated in cancers being treated with curative 
intent
WHAT THIS STUDY ADDS
ASyMS is an effective intervention for reducing symptom burden and improving 
quality of life during adjuvant chemotherapy for people with breast cancer, 
colorectal cancer, Hodgkin’s disease, and non-Hodgkin’s lymphoma
ASyMS has a positive effect on a range of additional important outcomes for 
patients during chemotherapy, including anxiety and self-efficacy
Digital solutions for remote monitoring and managing of chemotherapy 
symptoms can be delivered across multiple sites in European countries with 
diverse healthcare systems
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are often poorly controlled.1 2 Undertreatment of 
symptoms results in poorer adherence to treatment, 
impaired health related quality of life, increased 
health service use, and mortality.3-5 Current symptom 
assessment mechanisms rely on patients recognising 
that symptoms are severe enough to warrant reporting. 
Uncertainty, delayed reporting, and inability to access 
24 hour services frequently lead to toxicities not being 
recognised sufficiently quickly, placing patients’ safety 
at risk.6 7 Solutions are needed to expedite this process 
to improve patients’ outcomes and reduce costs.
Emergence of connected health has driven 
proliferation of remote monitoring solutions to 
support patients in community settings.8 9 These seem 
to be beneficial for people receiving chemotherapy, 
as they can circumnavigate the need for retrospective 
assessment, a process believed to “provide a weaker 
insight into actual symptom burden” as a result of 
recall bias.5 Such systems also enable patients’ data 
to be relayed to clinicians within minutes, enabling 
proactive symptom management. Previous research 
on remote monitoring systems in the chemotherapy 
context highlights their benefits for health related 
quality of life, symptom alleviation, avoiding 
unscheduled hospital admissions, survival, and 
cost effectiveness.10-14 However, this evidence is 
largely derived from trials, of short duration and 
from a single site/country, in people with advanced 
disease and without health economic evaluation.15 
16 Evidence to inform scale-up across multiple 
countries and enable benefits to be realised globally 
is also limited.17
eSMART aimed to provide definitive high quality 
evidence on large scale benefits of remote monitoring 
in the management of toxicities of adjuvant and first 
line chemotherapy. eSMART was underpinned by 
earlier work, reflecting the Medical Research Council’s 
framework for designing and evaluating complex 
interventions.18 19 This showed the feasibility and 
acceptability of the Advanced Symptom Management 
System (ASyMS).20-23 The trial hypothesis was that, 
compared with standard care, ASyMS would lead to 
reductions in symptom burden, supportive care needs, 
anxiety, and work limitations and improvements in 
health related quality of life and self-care/self-efficacy 
during chemotherapy treatment in patients with breast 
cancer, colorectal cancer, Hodgkin’s disease, or non-
Hodgkin’s lymphoma.
Methods
We conducted a multicentre, parallel group 
randomised controlled trial, using 1:1 allocation 
of study participants, between 31 March 2016 and 
31 March 2019 (recruitment closed 14 December 
2018). No significant changes were made to the 
methods during the trial,24 which was registered on 
Clinicaltrials.gov (NCT02356081). A data monitoring 
committee monitored progress and patient safety and 
met on average six monthly. The study is reported 
in accordance with the CONSORT statement for 
randomised controlled trials.
Setting and participants
Clinical or research staff from 12 cancer centres across 
Austria, Greece, Ireland, Norway, and the UK recruited 
participants. Participants attended for an enrolment 
visit before their first chemotherapy cycle, and written 
informed consent was obtained at this visit.
Eligible patients were aged ≥18 years; diagnosed 
as having breast cancer, colorectal cancer, Hodgkin’s 
disease, or non-Hodgkin’s lymphoma; scheduled 
to receive at least three cycles of two, three, or 
four weekly first line adjuvant chemotherapy or 
chemotherapy for the first time in five years; physically 
and psychologically fit to participate; and able to 
understand and communicate in the language of the 
country where recruited. The inclusion criteria were 
intentionally narrow to ensure that only patients 
treated with curative intent were recruited.
Participants were ineligible if they had distant 
metastasis (breast or colorectal cancer) or B 
symptoms (Hodgkin’s disease/non-Hodgkin’s 
lymphoma), were receiving concurrent radiotherapy 
or weekly chemotherapy (as timeframes covered by 
outcome measures were incompatible with weekly 
administration), had been diagnosed as having cancer 
or received chemotherapy within the previous five 
years, or were unable to provide informed consent.
Patients were initially recruited for the full duration 
of their chemotherapy. However, after five months, 
this was amended to participation for a maximum of 
six cycles to support recruitment and study timelines. 
This change was supported by previous ASyMS pilot 
work (unpublished) and literature showing that 
chemotherapy related symptoms are greatest during 
initial cycles of treatment.25 Consequently, participants 
used ASyMS when they were likely to gain most benefit.
Intervention
ASyMS (fig 1) provides real time, 24 hour monitoring 
and management of chemotherapy toxicity. Patients 
use ASyMS to complete a validated self-reported 
questionnaire (Daily Chemotherapy Toxicity Self-
Assessment Questionnaire (DCTAQ)) that assesses 10 
symptoms (nausea, vomiting, diarrhoea, constipation, 
mucositis, paraesthesia, sore hands/feet, flu-like 
symptoms/infection, tiredness, pain) and up to six 
additional symptoms.26 Patients are also asked to take 
and enter their body temperature by using a digital 
thermometer. Patients can access tailored, evidence 
based self-care advice (adapted from Macmillan Cancer 
Support resources) on ASyMS at any time.
ASyMS was translated into native languages 
(patient/clinician handsets, website, manuals). 
Patients completed the DCTAQ daily and whenever 
they felt unwell. “Real time” information was sent via 
a secure connection to the ASyMS server hosted by 
Docobo (https://www.docobo.co.uk/). After a review of 
local, national, and European best practice symptom 
management guidelines, and based on previous 
ASyMS studies, an evidence based clinical decision 
system, incorporating a symptom alerting algorithm 
and symptom specific management protocols, was 
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developed for ASyMS and verified by cancer experts 
from each clinical site before use.27
Symptom data were automatically evaluated in 
ASyMS and, when necessary, generated two types 
of alerts to hospital clinicians: amber, for persistent 
mild-moderate symptoms for which early intervention 
could prevent progression; and red, for chemotherapy 
emergencies such as neutropenic sepsis. Required 
response times were eight hours for amber alerts and 
30 minutes for red alerts. When an alert was generated 
before an earlier alert had been dealt with (for example, 
if the patient completed a subsequent DCTAQ because 
symptoms had worsened), the alerts were linked.
Clinicians received alerts on dedicated handsets. For 
red alerts, clinicians were required to review patients’ 
symptom reports on ASyMS web pages and contact the 
patient for further review. For amber alerts, although 
viewing of reports was required, clinicians had the 
option of contacting patients. This discretionary 
element was incorporated following piloting in which 
clinicians indicated that in instances when a patient 
had generated an amber alert and had received self-
care advice the previous day, contacting the patient 
the next day was often not necessary if the same 
alert was triggered again. During calls with patients, 
clinicians worked through evidence based clinical 
decision support systems embedded within ASyMS (fig 
2) to inform symptom management interventions. On 
closing the alert, clinicians detailed actions taken—
for example, self-care or acute oncology referral—and 
could select more than one action.
Participants in the intervention group used ASyMS 
for up to six cycles. They were trained by researchers/
clinicians at each site on its use before starting 
chemotherapy. Participants in the control group 
received care as usual at their cancer centre and 
were advised to contact their clinician(s) through 
standard mechanisms (usually telephone triage) 
if they developed symptoms. This group received 
clinical input in line with each local site’s standard 
advice (verbal and written) on chemotherapy related 
symptoms and self-care.
Outcome measures
All participants completed patient reported outcome 
measures recording primary and secondary outcomes 
at baseline (enrolment, before randomisation, before 
chemotherapy) and before subsequent cycles. Patient 
reported outcome measures were collected in the 
cancer centre, via a tablet or secure weblink, coinciding 
with chemotherapy visits.
We collected data on adverse events and hospital 
admissions by reviewing case notes. Specifically, we 
defined a “neutropenic sepsis event” as development 
of fever (oral temperature >38.5°C or two consecutive 
readings of >38.0°C for two hours) and other signs of 
generalised, whole body infection in a patient with 
neutropenia (an absolute neutrophil count <0.5×109/L, 
or <1.0×109/L and “falling”). We also investigated 
hypothermia in the presence of neutropenia as a sign 
of neutropenic sepsis.28 Device related incidents were 
monitored during the trial according to European 
Patient at home











Monitoring at clinical site
Receive and manage alerts
Alert response from
clinician to patient
Fig 1 | Advanced Symptom Management System (ASyMS) intervention. DCTAQ=Daily Chemotherapy Toxicity Self-
Assessment Questionnaire
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Commission DG Enterprise and Industry guidelines on 
a medical devices vigilance system.29
The primary outcome measure was the Memorial 
Symptom Assessment Scale (MSAS),30 which measures 
32 physical and psychological cancer related symptoms. 
Respondents reported on the occurrence, frequency, 
and severity of, and the distress associated with, each 
symptom over the preceding week. We calculated 
total MSAS score, representing symptom burden, by 
averaging items (that is, a potential range of 0-4). If >13% 
of items were missing, we treated the score as missing.30 
Additionally, we calculated three subscale scores (global 
distress index, physical score, and psychological score) 
and treated them as secondary outcomes. The reliability 
and validity of MSAS are well established; in this study 
Cronbach’s α for total MSAS and MSAS physical, MSAS 
psychological, and MSAS global distress index subscales 
was 0.87, 0.82, 0.77, and 0.83, respectively.
Full details of the secondary outcomes measures are 
published in the eSMART study protocol.24 Briefly they 
included Functional Assessment of Cancer Therapy—
General (FACT-G),31 assessing health related quality of 
life and four domains of wellbeing (physical, social/
family, emotional, and functional); Supportive Care 
Needs Survey Short-Form (SCNS-SF34),32 measuring 
supportive care needs in five domains (health system 
and information, psychological needs, physical and 
daily living, patient care and support, and sexual 
related); State-Trait Anxiety Inventory—Revised 
(STAI-R),33 measuring two types of anxiety (state 
(about an event) and trait (anxiety as a personal 
characteristic)); Communication and Attitudinal Self-
Efficacy scale for cancer (CASE-Cancer),34 assessing 
cancer patients’ confidence and ability to engage in 
their care plus three dimensions (maintaining a positive 
attitude, understanding and participating in care, 
and seeking and obtaining information); and Work 
Limitations Questionnaire (WLQ),35 a 25 item scale 
corresponding to four domains (time management, 
physical demands, mental/interpersonal demands, 
and output demands), which was completed only by 
participants who were working.
Additional secondary outcomes assessed the 
effectiveness of ASyMS one year after the randomised 
controlled trial, evaluated the cost effectiveness of 
ASyMS, and assessed changes in clinical practice. 
Emergency services
Emergency services
Acute oncology urgent assessment and review
Run ASyMS symptom questionnaire againComplete alert closure screen on ASyMS system
Potential dehydration or malnutrition? Potential shock?
Significant vomiting? HCP goes through ASyMS symptom
questionnaire (DCTAQ) with patient again and
type and level of alert (red/amber) is reassessed
Acute oncology urgent assessment and review
YesNo








Immediately life threatening assessment
(eg, is patient unconscious or not breathing?)
Signs and symptoms of infection?
(eg, high temperature or cough)
Initial assessment
“Since you last filled in your ASyMS questionnaire
  has the “symptom(s)” worsened?”
“Have you any new symptoms since you last
  filled in your ASyMS questionnaire?”
Evidence based nursing interventions
(eg, review anti-emetic
medication(s), investigate causes)
Fig 2 | Overview of example symptom management protocol (nausea and vomiting) on Advanced Symptom 
Management System (ASyMS). DCTAQ=Daily Chemotherapy Toxicity Self-Assessment Questionnaire; HCP=healthcare 
professional
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These secondary outcomes will be reported in 
forthcoming publications.
Adherence of patients and clinicians to intervention
We measured patients’ adherence by calculating 
compliance with DCTAQ for each patient, defined 
as the number of days on which at least one DCTAQ 
was completed divided by the number of days when 
a DCTAQ was available for completion. Participants 
were instructed to complete the DCTAQ daily but could 
complete additional DCTAQs any time they felt unwell. 
We calculated adherence rates by using the number of 
days on which DCTAQs were completed, rather than 
the number of DCTAQs completed, as participants may 
have completed more than one per day, over-inflating 
adherence rates. We calculated clinical adherence by 
measuring time taken for clinicians to first view ASyMS 
alerts on the server and calculating the percentage 
of linked amber and red alerts managed within the 
specified timeframes.
Randomisation and blinding
Surrey Clinical Trials Unit randomised patients 
remotely and independently using the Promasys 
system after patient consent and completion of 
baseline patient reported outcome measures and 
before the first chemotherapy cycle. Randomisation 
was stratified by site and cancer type. Research 
staff accessed the Promasys system remotely and 
completed a web based electronic case report form 
for the participant, and the allocation was assigned 
automatically. Random allocations were programmed 
by statisticians at the clinical trials unit using proc 
plan in SAS and run by staff independent of the trial 
team to ensure concealment of allocation. The nature 
of the intervention meant that blinding of patients 
was not possible, but patients were blinded to study 
hypotheses. Blinding of evaluators was achieved, 
as participants’ allocation was concealed from the 
statistical analysis team.
Sample size
During the planning of the trial, only limited literature 
was available, and it focused on the short version of 
MSAS (MSAS-SF) and on single patient groups followed 
over time. Chang et al reported clinically significant 
differences of 0.20-0.66 for a change in total MSAS-SF 
scores from baseline to one week later in patients with 
the worst cancer pain,36 and Dapueto et al reported 
absolute difference in global distress index of 0.38 
and a Cohen’s effect size of 0.6 for a change in MSAS-
SF global distress index scores between the first cycle 
and third month of adjuvant chemotherapy.37 Given the 
lack of data on MSAS from intervention studies, a priori 
we considered a small to moderate Cohen’s effect size of 
0.25 to be a clinically significant difference in total MSAS 
scores. We then based sample size estimation based on 
differences in total MSAS scores between intervention 
and control groups of 1.45–1.30=0.15 from a previous 
randomised controlled trial.38 For a difference in 
total MSAS scores of 0.15 (SD 0.6), with baseline and 
four repeated measures after enrolment, we needed 
a sample of 776 participants (110 participants with 
Hodgkin’s disease or non-Hodgkin’s lymphoma, 333 
participants with breast cancer, and 333 patients with 
colorectal cancer) to provide 90% power for a two sided 
hypothesis test at the 5% significance level. Allowing 
for 30% attrition, we increased the total study sample 
size to 1108. By February 2017 the attrition rate was 
lower than anticipated (10%); consequently, we 
reduced the sample size to 862.
Data analysis
We did an intention to treat analysis. We present 
study outcomes as means and standard deviations or 
percentages and denominators. Transformations were 
needed when distributions were non-normal, and we 
present medians and ranges. We present enrolment 
characteristics for the evaluable intention to treat sample. 
The primary outcome of total MSAS score is continuous, 
and we assessed it in a repeated measures analysis 
using linear and non-linear mixed models. We used a 
mixed model repeated measures analysis that uses all 
available data, assuming data are missing at random, 
throughout the analyses. Many participants rated their 
symptoms as not present (that is, 0), so the mixed model 
was implemented with a zero inflated γ distribution and 
identity link to provide results on the original scale.
Analyses tested the between group difference in 
means for the primary outcome—total symptom burden 
(total MSAS)—during chemotherapy for up to six cycles. 
We tested the primary hypothesis (reduced symptom 
burden in the intervention group over six cycles) 
through the regression parameter for the intervention 
versus control group, adjusting for baseline MSAS. We 
also adjusted for pre-specified variables: cancer type 
(breast cancer, colorectal cancer, Hodgkin’s disease, 
non-Hodgkin’s lymphoma), age (years), sex (male, 
female), number of comorbidities (0, 1-4, ≥5), and 
country (Austria, Greece, Republic of Ireland, Norway, 
and UK). We did pre-specified subgroup analyses by 
fitting trial arm by subgroup interaction parameters. If 
this test was significant at the 5% level, we estimated 
results separately for different subgroups. We used 
SAS software (version 9.4) and R 3.5 for all statistical 
analyses. We took a two sided P value of <0.05 as 
significant for all analyses unless otherwise specified.
Patient and public involvement
The European Cancer Patient Coalition was a partner 
in eSMART and advised throughout the study. It 
was involved in setting research priorities, defining 
research questions and outcome measures, and 




We recruited 840 patients; seven participants in 
the intervention group and four in the control group 
were ineligible after randomisation or immediately 
withdrew consent, leaving 415 and 414 analysable 
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Fig 3 | CONSORT diagram for eSMART. *Some people reported more than one reason for not wanting to take part, so total number of reasons exceeds 
number declined/excluded
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(fig 3). Not all the patients recruited participated 
for six cycles of chemotherapy. Reasons varied 
but included prescription of less than six cycles, 
discontinuation of chemotherapy, withdrawal, and 
death. Most participants (n=723; 87.2%) completed 
four to six cycles. Attrition was low at 8.2% (n=34) 
in the intervention group and 9.2% (n=38) in the 
control group. Figure 3 provides details for the primary 
outcome, noting the number expected, the number not 
collected/not analysable, and the number analysed.
Enrolment characteristics
Randomisation achieved a good balance between study 
arms for age, sex, country, cancer type, employment, 
and educational status (more in the intervention group 
reported a higher degree). Mean age was 52.4 (SD 
12.2) years, and 81.8% were female. Breast cancer was 
most common (71.4%), and most had early stage (0-II) 
disease (53.4%). The greatest numbers of participants 
were recruited from the UK (31.7%) and Greece 
(31.2%). Half had no comorbidities (table 1).
Primary outcome
Table 2 shows mean total MSAS scores for the 
intervention and control groups at each assessment. 
In the intervention group, symptom burden remained 
at pre-chemotherapy treatment levels over all six 
chemotherapy cycles. By contrast, the control group 
reported an increase from cycle 1, which then slowly 
reduced over the five subsequent chemotherapy cycles. 
Using an identity link to give results on the original 
scale, the adjusted analysis least squares means on 
repeated measures were 0.36 in the intervention arm 
and 0.52 in the standard care arm, giving a difference 
of −0.15 (95% confidence interval −0.19 to-0.12; 
P<0.001) in favour of the intervention (table 3). This is 
equivalent to a Cohen’s effect size of 0.5.
Separate analyses for MSAS sub-domains (table 3) 
showed that mean MSAS global distress index and 
MSAS psychological scores decreased in both groups 
once chemotherapy started. However, they were 
consistently lower in the intervention group during the 
trial. Least squares mean was 0.46 in the intervention 
group compared with 0.67 in the control group, giving 
a difference of −0.21 (−0.27 to −0.16; P<0.001) for 
MSAS global distress index (effect size 0.42). For MSAS 
psychological, the mean difference was −0.16 (−0.23 to 
−0.10; P<0.001) and the effect size was 0.27. By contrast, 
the MSAS physical score rose during chemotherapy 
but less so in the intervention arm (0.33 v 0.54, with a 
difference of −0.21 (−0.26 to −0.17; P<0.001) in favour 
of the intervention and an effect size of 0.58.
In the adjusted analyses, both country and cancer 
type were related to patient reported outcome 
measure scores. MSAS scores were generally lower in 
participants with Hodgkin’s disease or non-Hodgkin’s 
lymphoma compared with breast or colorectal cancer. 
Moreover, MSAS scores in UK participants tended to 
be similar to those from Norway and Ireland, whereas 
scores from Austria and Greece were significantly 
lower than those from the UK. However, subgroup 
analyses by country and type of cancer showed that 
although benefits were seen in all groups, the greatest 
benefits of the intervention were in participants with 
breast cancer, Hodgkin’s disease, or non-Hodgkin’s 
lymphoma in Austria, Ireland, or the UK.
Secondary outcomes
FACT-G scores were higher in the intervention group 
than the control group across all cycles (table 3) 
(mean difference 4.06, 95% confidence interval 2.65 
to 5.46; P<0.001). Similarly, we found a statistically 
significant between group mean difference in favour 
of the intervention group on FACT-G physical (mean 
difference 1.75, 1.25 to 2.25; P<0.001) and functional 
(1.61, 1.00 to 2.22; P<0.001) domains. The between 
group mean differences for the FACT-G emotional and 
social domains were not statistically significant.
We found statistically significant between group 
differences for mean scores for STAI-R trait anxiety 
(table 3) (−1.15, –1.90 to –0.41; P=0.003) and STAI-R 
state anxiety (–1.13, –2.06 to –0.20; P=0.02) in favour 
of the intervention group. The intervention group 
reported greater self-care self-efficacy than the control 
group (0.85, 0.19 to 1.50; P=0.01).
Supportive care needs tended to be lower for most 
SCNS-SF34 domains in the intervention group (table 
3). Psychological needs followed the same trend as 
MSAS, with a decrease once chemotherapy started 
and a larger decrease in the intervention group. The 
largest observed benefits in the intervention group 
were for sexuality needs (−1.56, −3.11 to −0.01; 
P<0.05), patient care and support needs (−1.74, −3.31 
to −0.16; P=0.03), and physical and daily living needs 
(−2.8, −5.0 to −0.6; P=0.01). We found no statistically 
significant differences for the health system and 
information needs domain.
CASE-Cancer scores were higher in the intervention 
group than in the control group (mean difference 0.81, 
0.19 to 1.43; P=0.01). The WLQ was completed by the 
251 patients who were employed, and no significant 
differences were noted.
Adherence to the intervention and alert outcomes
DCTAQ adherence was high for the intervention group 
at 76.9% (33 156 DCTAQs completed; 43 118 DCTAQs 
available). Of these, 3456 generated a red alert and 
3746 an amber alert. Some alerts were “linked,” 
resulting in 3389 (10.2%) linked red alerts and 3649 
(11.0%) linked amber alerts. Similarly, clinicians 
showed a high adherence rate in terms of dealing 
with ASyMS alerts within specified timeframes (95% 
of amber alerts and 85% of red alerts) (table 4). Most 
amber alerts were managed by using self-care advice 
(n=2241; 60.6%) and acute oncology referral (n=507; 
13.7%). For red alerts, self-care (n=1658; 48.0%) and 
acute oncology referral (n=1207; 35.0%) were also the 
two most common alert outcomes (table 5).
Adverse events
Adverse events were balanced across study arms. Three 
deaths occurred in each group. Neutropenic events 
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were higher in the intervention group (125 (64%) v 
71 (36%)). This was expected, as remote monitoring 
sought to identify these. The numbers of planned (34 
v 38) and unplanned hospital admissions (120 v 109) 
were similar in the two groups (table 6). No ASyMS 
device related incidents were reported.
Table 1 | Characteristics of participants at enrolment. Values are numbers (percentages) unless stated otherwise
Characteristics All participants (n=829) Intervention group (n=415) Standard care group (n=414)
Mean (SD) age 52.4 (12.2) 51.9 (12.4) 52.9 (12.1)
Female sex 678 (81.8) 340 (81.9) 338 (81.6)
Marital status:
 Married 553 (66.7) 273 (65.8) 280 (67.6)
 Single 129 (15.6) 68 (16.4) 61 (14.7)
 Divorced 87 (10.5) 45 (10.8) 42 (10.1)
 Widowed 38 (4.6) 14 (3.4) 24 (5.8)
 Not known 22 (2.7) 15 (3.6) 7 (1.7)
Education:
 Primary 60 (7.2) 30 (7.2) 30 (7.2)
 Secondary 318 (38.4) 141 (34.0) 177 (42.8)
 University 439 (53.0) 235 (56.6) 204 (49.3)
 Not known 12 (1.4) 9 (2.2) 3 (0.7)
Employment:
 Full time 375 (45.2) 192 (46.3) 183 (44.2)
 Part time 109 (13.1) 53 (12.8) 56 (13.5)
 Home maker 82 (9.9) 40 (9.6) 42 (10.1)
 Unemployed 67 (8.1) 34 (8.2) 33 (8.0)
 Retired 173 (20.9) 82 (19.8) 91 (22.0)
 Rather not say 23 (2.8) 14 (3.4) 9 (2.2)
Smoking:
 Never 414 (49.9) 214 (51.6) 200 (48.3)
 Ex-smoker 280 (33.8) 133 (32.0) 147 (35.5)
 Not every day 38 (4.6) 16 (3.9) 22 (5.3)
 Every day 97 (11.7) 52 (12.5) 45 (10.9)
Alcohol consumption:
 Every day 32 (3.9) 18 (4.3) 14 (3.4)
 Occasionally 593 (71.5) 306 (73.7) 287 (69.3)
 Never 204 (24.6) 91 (21.9) 113 (27.3)
Country:
 Austria 140 (16.9) 71 (17.1) 69 (16.7)
 Greece 259 (31.2) 127 (30.6) 132 (31.9)
 Ireland 135 (16.3) 68 (16.4) 67 (16.2)
 Norway 32 (3.9) 16 (3.9) 16 (3.9)
 UK 263 (31.7) 133 (32.0) 130 (31.4)
No of comorbidities:
 0 420 (50.7) 220 (53.0) 200 (48.3)
 1-4 393 (47.4) 188 (45.3) 205 (49.5)
 ≥5 16 (1.9) 7 (1.7) 9 (2.2)
Staging*:
 Stage 0 3 (0.4) 2 (0.5) 1 (0.2)
 Stage I 129 (15.6) 63 (15.2) 66 (15.9)
 Stage II 310 (37.4) 154 (37.1) 156 (37.7)
 Stage III 310 (37.4) 157 (37.8) 153 (37.0)
 Stage IV† 21 (2.5) 10 (2.4) 11 (2.7)
 Undefined‡ 56 (6.8) 29 (7.0) 27 (6.5)
No of chemotherapy cycles:
 1 3 (0.4) 3 (0.7) 0
 2 4 (0.5) 3 (0.7) 1 (0.2)
 3 19 (2.3) 12 (2.9) 7 (1.7)
 4 192 (23.2) 95 (22.9) 97 (23.4)
 5 27 (3.3) 14 (3.4) 13 (3.1)
 6 504 (60.8) 248 (59.8) 256 (61.8)
 7§ 10 (1.2) 8 (1.9) 2 (0.5)
 8§ 65 (7.8) 30 (7.2) 35 (8.5)
 12§ 5 (0.6) 2 (0.5) 3 (0.7)
Median (range) No of 
chemotherapy cycles
6 (1-12) 6 (1-12) 6 (2-12)
*TNM/UICC system for breast/colorectal cancer; Ann Arbor Staging System for haematological cancers.
†Not an exclusion criterion for participants with haematological cancer.
‡Data not captured at clinical site before end of trial.
§Until substantial amendment to study protocol was made to limit patients’ participation to ≤6 chemotherapy cycles, first 80 patients enrolled in trial 
participated until end of their prescribed chemotherapy protocol, and therefore show as having completed >6 cycles.
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Discussion
To our knowledge, this trial is the first to evaluate 
the efficacy of real time remote monitoring of 
chemotherapy toxicity across multiple countries and 
to focus mainly on people being treated with curative 
intent. Overall, symptom burden in the intervention 
group was effectively controlled, remaining at pre-
treatment levels throughout the trial. Similar findings 
have been reported previously; however, these earlier 
studies were conducted in a single country and 
healthcare system.10-13
The greatest improvements were seen in patients 
with breast cancer, Hodgkin’s disease, or non-
Hodgkin’s lymphoma in Austria, Ireland, and the UK. 
Reasons for differences are unclear, but because ASyMS 
was developed in the UK it may work best in similar 
healthcare systems. However, why symptom burden 
was higher in Norwegian participants is not clear, 
although it may be because the number of patients 
from Norway was insufficient to show any difference. 
eSMART, like other studies,11 12 found changes in 
symptom burden over consecutive chemotherapy 
cycles. Our findings suggest that benefits of remote 
monitoring begin within the first three cycles of 
treatment and are sustained over time, indicating that 
systems such as ASyMS should be implemented at the 
start of treatment.
Patients in the intervention group attributed 
improvements when using ASyMS in terms of enabling 
real time reporting, the embedded alert algorithms, 
and direct links to their hospital and oncology team, 
all of which facilitated timely access to quality care. 
Similarly, clinicians’ experiences indicated that 
clinical algorithms and real time symptom reporting 
enabled provision of targeted and more effective 
interventions for symptoms. Forthcoming publications 
will report on patients’ and clinicians’ experiences of 
the intervention in more detail.
We considered, by convention, that the larger the 
Cohen’s effect size beyond the 0.25 cut-off point the 
stronger the indication is for a clinically important 
change in our primary outcome between intervention 
and control. From the perspective of clinical 
importance, the mean between group difference of 
0.15 in total MSAS scores translated into an effect size 
Table 2 | Descriptive summary of primary outcome – total Memorial Symptom 
Assessment Scale (MSAS) and sub-domains
Intervention group Standard care group
No Mean (SD) Median (range) No Mean (SD) Median (range)
Total MSAS
Baseline 407 0.35 (0.30) 0.27 (0-1.62) 393 0.39 (0.31) 0.32 (0-1.94)
Cycle 1 367 0.33 (0.27) 0.25 (0-1.35) 340 0.51 (0.42) 0.40 (0-2.50)
Cycle 2 360 0.35 (0.28) 0.28 (0-1.98) 334 0.53 (0.40) 0.44 (0-2.25)
Cycle 3 343 0.35 (0.31) 0.28 (0-1.45) 320 0.52 (0.44) 0.43 (0-3.24)
Cycle 4 304 0.37 (0.31) 0.31 (0-1.62) 280 0.53 (0.44) 0.45 (0-3.04)
Cycle 5 246 0.34 (0.29) 0.27 (0-1.45) 229 0.52 (0.41) 0.44 (0-2.22)
Cycle 6 179 0.37 (0.28) 0.30 (0-1.39) 157 0.48 (0.39) 0.38 (0-1.88)
MSAS global distress index
Baseline 406 0.66 (0.55) 0.56 (0. 3.24) 393 0.73 (0.55) 0.60 (0-3.36)
Cycle 1 366 0.42 (0.47) 0.25 (0-2.36) 337 0.66 (0.62) 0.48 (0-3.14)
Cycle 2 361 0.42 (0.46) 0.28 (0-3.08) 334 0.67 (0.61) 0.51 (0-3.12)
Cycle 3 343 0.44 (0.49) 0.28 (0-2.46) 318 0.70 (0.64) 0.56 (0-3.48)
Cycle 4 304 0.46 (0.46) 0.32 (0-2.18) 277 0.69 (0.65) 0.56 (0-3.58)
Cycle 5 246 0.42 (0.49) 0.27 (0-2.40) 227 0.67 (0.57) 0.56 (0-2.68)
Cycle 6 179 0.44 (0.46) 0.32 (0-2.46) 157 0.62 (0.58) 0.44 (0-2.80)
MSAS psychological
Baseline 400 0.90 (0.80) 0.67 (0-3.57) 388 1.00 (0.77) 0.84 (0-3.83)
Cycle 1 365 0.48 (0.60) 0.26 (0-3.08) 340 0.72 (0.74) 0.51 (0-3.90)
Cycle 2 359 0.46 (0.55) 0.31 (0-3.69) 334 0.68 (0.74) 0.46 (0-3.23)
Cycle 3 343 0.47 (0.61) 0.26 (0-3.07) 323 0.67 (0.74) 0.46 (0-3.74)
Cycle 4 304 0.51 (0.57) 0.31 (0-2.62) 280 0.69 (0.75) 0.46 (0-3.57)
Cycle 5 246 0.48 (0.64) 0.26 (0-3.59) 231 0.65 (0.69) 0.46 (0-3.46)
Cycle 6 179 0.52 (0.62) 0.31 (0-2.71) 157 0.64 (0.68) 0.51 (0-3.83)
MSAS physical
Baseline 406 0.27 (0.35) 0.15 (0-2.10) 395 0.31 (0.36) 0.20 (0-1.97)
Cycle 1 365 0.27 (0.31) 0.17 (0-1.54) 338 0.51 (0.47) 0.38 (0-2.36)
Cycle 2 360 0.31 (0.37) 0.19 (0-2.19) 336 0.54 (0.46) 0.46 (0-2.66)
Cycle 3 344 0.34 (0.38) 0.24 (0-2.07) 319 0.56 (0.50) 0.48 (0-3.28)
Cycle 4 305 0.35 (0.36) 0.25 (0-2.01) 280 0.57 (0.51) 0.47 (0-2.97)
Cycle 5 247 0.32 (0.34) 0.20 (0-1.51) 226 0.56 (0.47) 0.43 (0-2.26)
Cycle 6 179 0.34 (0.33) 0.26 (0-1.71) 157 0.49 (0.45) 0.38 (0-2.01)
Table 3 | Mixed model, repeated measures analysis of change from baseline using γ model
Variable
Adjusted* least squares mean (95% CI) Adjusted* mean difference (95% CI)
Intervention Standard care Intervention v standard care P value
Total MSAS† 0.36 (0.34 to 0.39) 0.52 (0.49 to 0.54) −0.15 (−0.19 to −0.12) <0.001
MSAS global distress index 0.46 (0.42 to 0.50) 0.67 (0.63 to 0.71) −0.21 (−0.27 to −0.16) <0.001
MSAS psychological 0.51 (0.46 to 0.55) 0.67 (0.63 to 0.72) −0.16 (−0.23 to −0.10) <0.001
MSAS physical 0.33 (0.30 to 0.36) 0.54 (0.51 to 0.58) −0.21 (−0.26 to −0.17) <0.001
FACT-G total 86.3 (85.3 to 87.3) 82.3 (81.3 to 83.3) 4.06 (2.65 to 5.46) <0.001
FACT-G physical 23.4 (21.3 to 23.7) 21.6 (21.3 to 22.0) 1.75 (1.25 to 2.25) <0.001
FACT-G emotional 20.4 (20.2 to 20.7) 19.9 (19.6 to 20.1) −0.54 (−1.23 to 0.16) 0.13
FACT-G social 23.6 (23.2 to 23.9) 23.2 (22.8 to 23.5) 0.44 (−0.06 to 0.93) 0.08
FACT-G functional 19.1 (18.7 to 19.5) 17.5 (17.1 to 17.9) 1.61 (1.00 to 2.22) <0.001
STAI-R trait 32.7 (32.2 to 33.3) 33.9 (33.4 to 34.4) −1.15 (−1.90 to −0.41) 0.003
STAI-R state 31.9 (31.2 to 32.6) 33.0 (32.4 to 33.7) −1.13 (−2.06 to −0.20) 0.02
CASE-Cancer 43.7 (43.3 to 44.2) 42.9 (42.3 to 43.4) 0.81 (0.19 to 1.43) 0.01
SCNS-SF34 psychological 23.2 (21.9 to 24.6) 24.4 (23.0 to 25.8) −1.14 (−3.04 to 0.75) 0.24
SCNS-SF34 health system and information 22.3 (21.1 to 23.4) 23.7 (22.5 to 24.9) −1.46 (−3.13 to 0.21) 0.09
SCNS-SF34 sexuality needs 12.0 (10.9 to13.1) 13.5 (12.4 to 14.7) −1.56 (−3.11 to −0.01) <0.05
SCNS-SF34 patient care and support 17.5 (16.5 to 18.6) 19.3 (18.1 to 20.4) −1.74 (−3.31 to −0.16) 0.03
SCNS-SF34 physical and daily living 27.3 (25.7 to 28.8) 30.0 (28.5 to 31.6) −2.8 (−5.0 to −0.6) 0.01
CASE-Cancer=Communication and Attitudinal Self-Efficacy scale for cancer; FACT-G=Functional Assessment of Cancer Therapy—General; MSAS=Memorial 
Symptom Assessment Scale; SCNS-SF34=Supportive Care Needs Survey Short-Form; STAI=State-Trait Anxiety Inventory.
*Adjusted for baseline patient reported outcome measure, cycle, age, sex, cancer type, comorbidity, and country.
†Primary outcome.
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of 0.5, which is considered “medium” according to 
Cohen’s criteria.39 This finding is promising and further 
substantiates our statistically significant results, 
pointing to a positive, clinical impact on symptom 
experience when self-reported symptoms were remotely 
monitored via ASyMS. Our Cohen’s effect sizes ranged 
between 0.42 and 0.58 and so are either comparable 
to or larger than previously reported effect sizes.36 37 
In a randomised controlled trial testing a symptom 
monitoring app during neoadjuvant chemotherapy 
for breast cancer, Fjell et al reported an effect size of 
0.26 for between group differences in total MSAS (and 
0.34 for MSAS global distress index scores) two weeks 
after treatment completion.40 Effect sizes of 0.01-0.21 
for between group differences in MSAS global distress 
index were reported in a randomised controlled trial of 
computerised patient reported symptom monitoring 
during one to four weeks of radiotherapy.41
eSMART showed significant improvements in 
anxiety, health related quality of life, self-efficacy, 
and supportive care needs in the intervention group. 
The improvements in health related quality of life 
are consistent with findings from recent trials using 
remote monitoring systems in chemotherapy care.42 
Although Basch et al reported similar results using 
the EuroQol five dimension (EQ-5D) questionnaire, the 
dimensions are assessed by a single item.12 We used 
a validated patient reported outcome measure that 
comprehensively assessed each of these outcomes and 
provides more detailed findings about the impact of 
remote monitoring systems not only on health related 
quality of life but also on self-efficacy and supportive 
care needs. Our findings suggest that ASyMS has a 
broader impact, but further analyses using techniques 
such as parallel process growth modelling are needed 
to evaluate concurrent changes in symptom burden 
and health related quality of life outcomes.
eSMART is the first randomised controlled trial 
in people with cancer to assess the effect of remote 
symptom monitoring on anxiety by using a validated 
patient reported outcome measure. ASyMS was 
associated with statistically significant improvements 
in anxiety. Our findings may differ from relatively small 
post-intervention effects on psychological symptoms 
reported in literature pertinent to routine use of 
patient reported outcome measures43; however, they 
are consistent with earlier studies of ASyMS in which 
participants reported feelings of enhanced safety and 
reassurance.20 21 23 44 Anxiety is the most common 
psychological symptom after a diagnosis of cancer and 
is higher among people with cancer than in the general 
population,45 46 so these effects may benefit a large 
proportion of oncology patients; however, this needs 
to be confirmed in future studies.
Patients using ASyMS reported a statistically 
significant improvement in self-efficacy, which is 
consistent with results from the eRAPID trial.11 Daily 
symptom reporting with real time clinician support for 
moderate-severe symptoms and provision of tailored 
self-care information are novel features of ASyMS 
and are likely to promote greater self-efficacy. Other 
remote monitoring systems that assess symptoms 
less frequently—for example, weekly12— may have 
limited potential to encourage patients to learn self-
management strategies. Likewise, providing real time 
support from clinicians may engender a greater sense 
of control. Although other systems integrate symptom 
reports with patients’ health records, they do not alert 
clinicians to contact patients within a specified time. 
Instead, the onus is on patients to contact clinicians 
when symptoms occur. Recent research on neutropenic 
sepsis showed that patients are reluctant to report 
symptoms in a timely manner.7
eSMART shows that ASyMS can reduce supportive 
care needs in several domains during chemotherapy, 
including psychological, physical, and daily living needs, 
patient care and support needs, and sexuality needs. The 
observed reductions may be partially explained by the 
significant reductions in anxiety and physical symptoms 
experienced by the intervention group. Daily reporting 
and feedback from clinicians may have been associated 
with the receipt of advice on managing physical side 
effects, with a concomitant decrease in physical and 
daily living needs. This enhanced symptom support may 
have resulted in patients perceiving that their clinicians 
were more sensitive to their needs and decreased their 
need for supportive care.
Needs relating to sexuality are often overlooked 
during treatment,47 48 so the comprehensive e-library of 
useful resources, with information on sexual wellbeing, 
Table 4 | Clinicians’ adherence to time when handling 
alerts
Type of alert
No of alerts 
generated
No of linked 
alerts
No (%) of linked 
alerts viewed within 
 timescale*
Red alert† 3456 3389 2883 (85.1)
Amber alert‡ 3746 3649 3467 (95.0)
Overall 7202 7038 6350 (90.2)
*Time was measured from when first linked alert arrived at server to 
time when clinician first viewed alert.
†Target time was 30 minutes.
‡Target time was 8 hours.
Table 5 | Clinical responses following Advanced Symptom Management System (ASyMS) 
alerts
Outcome No of amber alerts No of red alerts
Self-care 2241 1658
Acute oncology referral 507 1207
Patient not contacted 305 0
Other 317 257
Unable to contact patient; amber alert closed 150 -
No intervention recorded 60 178
Out of hours services 38 18
Emergency services referral 25 77
General practitioner referral 27 29
Hospital referral: clinic review 7 11
Hospital referral: general ward 6 5
Hospital referral: acute oncology referral 5 5
Hospital referral: emergency department 3 4
Hospital referral: specialist 3 2
District nurse referral 2 1
Palliative care team: hospital 2 1
Total* 3698 3453
*Totals are greater than number of alerts as healthcare professionals could select more than one outcome.
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may have been an easily accessible information 
source. Furthermore, because patients using ASyMS 
had reduced symptom burden and anxiety, and better 
health related quality of life, they may have been more 
inclined to engage in sexual activity.
Evaluating work limitations was an important 
component of eSMART given the impact of cancer 
treatment on employment.49 50 Work limitation 
scores were not statistically significantly different 
between the two groups. This finding is not consistent 
with a previous study that reported significant 
work limitations in patients undergoing curative 
chemotherapy.51 However, our results should be 
interpreted with caution, as only participants who 
were working completed this patient reported outcome 
measure.
Patients’ and clinicians’ adherence to the 
intervention was very good and compares favourably 
with similar studies that report slightly lower 
adherence rates,11 especially given that eSMART 
required daily assessments, which some people may 
consider onerous.
Importantly, our randomised controlled trial found 
that the safety of ASyMS was satisfactory, with no 
device related incidents reported. Adverse events were 
balanced between the two groups, each with three 
deaths and similar rates of hospital admission. This is 
not surprising, however, as hospital admission rates 
in this population are relatively low. The incidence of 
neutropenic events was higher in the intervention arm, 
but this was expected as greater identification was the 
intervention’s intent.
Approximately 30% of patients approached 
declined participation, with 27% not giving a reason. 
Those who did mainly cited the psychological impact 
of diagnosis and limited confidence with technology. 
Our take-up rate is similar to that in comparable 
studies that recruited a mix of participants being 
treated with curative and palliative intent and higher 
than in those that recruited patients with advanced 
disease.11 12 Anecdotally, clinicians also reported 
that the intensity of the study at a time when people 
were feeling stressed about starting treatment was a 
common concern of those who declined participation. 
However, the high patient adherence rates seen in this 
trial serve as a positive indicator of the usability and 
adoption of ASyMS by patients within the context of 
their chemotherapy treatment.
Strengths and limitations of study
This is the largest trial to date of remote monitoring 
of symptoms during chemotherapy for cancers being 
treated with curative intent. Notable strengths of 
this study include its robust randomised controlled 
trial design, fully powered sample size, longitudinal 
assessments of symptoms and outcomes, and multi-
diagnosis, multisite, and multi-country deployment. 
Our study, therefore, avoided many limitations of 
previous studies of remote monitoring that tended 
to evaluate deployment at single sites and to 
recruit patients from a single diagnostic group. Our 
attrition rate was considerably lower than expected 
and comparable to those in similar studies,11 12 
demonstrating external validity and high acceptability 
of the intervention to patients and clinicians.
Our study does, however, have limitations. Firstly, 
almost three quarters of participants had breast 
cancer and were female; however, this is a common 
limitation of supportive cancer care research and 
reflects the high incidence of breast cancer in Europe. 
Careful consideration was given before clinical sites 
were permitted to recruit greater numbers of patients 
with breast cancer than originally intended, but we 
judged it more important that the study achieved 
power than that the proposed diagnostic breakdown 
was achieved without sufficient power. We recruited 
participants with Hodgkin’s disease, non-Hodgkin’s 
lymphoma, and colorectal cancer, so we have evidence 
that ASyMS could be beneficial in these populations 
as well. However, with a small number of participants 
with Hodgkin’s disease or non-Hodgkin’s lymphoma, 
a larger study is warranted. Seven patients were 
excluded after randomisation, but associated bias was 
reduced as numbers were equally distributed between 
the study groups. Although patients and clinicians 
were aware of the allocation, trial statisticians 
were blinded throughout the analysis. Finally, we 
encountered technical challenges across all sites owing 
to the connectivity of ASyMS SIM cards, meaning that 
patients using ASyMS reverted to standard care for 
approximately two weeks to ensure patient safety 
while this technical problem was resolved. Although 
technical testing indicated that this was not related to 
the ASyMS device, it may have affected overall eSMART 
results.
Implications for clinicians and for policy
The results of eSMART support the use of remote 
symptom monitoring in routine care for patients treated 
with curative intent. When combined with findings 
of comparable randomised controlled trials,10  12 52 
these results support the incorporation of remote 
symptom monitoring technologies into evidence based 
guidelines on symptom management in people with 
cancer. Governments and health organisations are 
increasingly responding to the rapidly evolving digital 
health landscape to provide optimal services and care—
even more so in response to the covid-19 pandemic—
and they recognise ways in which these technologies 
can disrupt, and are disrupting, the status quo.53 
Many government policies prioritise empowerment 
of citizens, enhanced self-management, and digitally 
enabled access to services.54 Our findings suggest that 
Table 6 | Adverse events. Values are numbers (percentages)
Adverse event All patients Intervention group Normal care group
Death* 6 3 (50) 3 (50)
Neutropenic sepsis event† 196 125 (64) 71 (36)
Planned hospital admission† 72 34 (47) 38 (53)
Unplanned hospital admission† 229 120 (52) 109 (48)
*Collected in Promasys.
†Collected in case note reviews.
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an evidence based remote monitoring intervention, 
such as ASyMS, has potential for implementation into 
routine care to make a meaningful difference to people 
with cancer.
Conclusion
The results of eSMART suggest that ASyMS is an 
effective intervention for reducing symptom burden 
and improving health related quality of life during 
adjuvant chemotherapy across a range of cancers. Use 
of ASyMS was associated with significant reductions in 
anxiety and improvements in several supportive care 
needs and self-efficacy domains. Moreover, results were 
consistent across five European countries, although 
perhaps with greater impact in Austria, the Republic 
of Ireland, and the UK. Our success in implementing 
ASyMS across several diverse health systems suggests 
that the system can be easily scaled up and adapted for 
use in various international settings.
Improving symptom management by using remote 
monitoring systems such as ASyMS is essential. 
Future research should combine artificial intelligence 
with the use of real world data to develop predictive, 
personalised, and targeted interventions. These 
approaches are likely to lead to improvements in 
patients’ outcomes and efficiencies in care. Evaluation 
of the efficacy of remote symptom monitoring systems 
such as ASyMS for other treatment modalities (for 
example, targeted therapies) is needed. The ultimate 
vision is to have a multimodal seamless system of 
remote symptom monitoring used from the start of 
treatment and through survivorship.
Our findings are relevant in the context of the covid-19 
pandemic. The cancer community faces unprecedented 
challenges in delivering chemotherapy,55 but ASyMS 
can provide a safe, secure, and “real time” system 
that optimises symptom management and supports 
patients to remain at home. Essentially, the system can 
expedite informed and appropriate patient triage and 
enable clinicians to care for multiple patients in real 
time, using digital lines of communication to deliver 
high quality and safe care at a distance.
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